See GLP-1 in All languages combined, or Wiktionary
{
"forms": [
{
"form": "GLP-1s",
"tags": [
"plural"
]
}
],
"head_templates": [
{
"args": {
"1": "~",
"head": "GLP-1"
},
"expansion": "GLP-1 (countable and uncountable, plural GLP-1s)",
"name": "en-noun"
}
],
"lang": "English",
"lang_code": "en",
"pos": "noun",
"senses": [
{
"alt_of": [
{
"extra": "an incretin (gastrointestinal hormone)",
"word": "glucagon-like peptide-1"
}
],
"categories": [
{
"kind": "other",
"langcode": "en",
"name": "Hormones",
"orig": "en:Hormones",
"parents": [],
"source": "w"
}
],
"glosses": [
"Initialism of glucagon-like peptide-1, an incretin (gastrointestinal hormone)."
],
"id": "en-GLP-1-en-noun-Ng7xN7nu",
"links": [
[
"biochemistry",
"biochemistry"
],
[
"glucagon-like peptide-1",
"w:glucagon-like peptide-1"
],
[
"incretin",
"incretin"
],
[
"gastrointestinal",
"gastrointestinal"
],
[
"hormone",
"hormone"
]
],
"raw_glosses": [
"(biochemistry) Initialism of glucagon-like peptide-1, an incretin (gastrointestinal hormone)."
],
"tags": [
"abbreviation",
"alt-of",
"countable",
"initialism",
"uncountable"
],
"topics": [
"biochemistry",
"biology",
"chemistry",
"microbiology",
"natural-sciences",
"physical-sciences"
]
},
{
"alt_of": [
{
"extra": "(“glucagon-like peptide-1 receptor agonist”), a class of drugs used for the medication of diabetes and weight loss",
"word": "GLP-1 RA"
}
],
"categories": [
{
"_dis": "15 85",
"kind": "other",
"name": "English entries with incorrect language header",
"parents": [],
"source": "w+disamb"
},
{
"_dis": "8 92",
"kind": "other",
"name": "English words spelled without vowels",
"parents": [],
"source": "w+disamb"
},
{
"_dis": "14 86",
"kind": "other",
"name": "Pages with 1 entry",
"parents": [],
"source": "w+disamb"
},
{
"_dis": "14 86",
"kind": "other",
"name": "Pages with entries",
"parents": [],
"source": "w+disamb"
}
],
"examples": [
{
"bold_text_offsets": [
[
3,
8
]
],
"ref": "2023 October 9, Tressie McMillan Cottom, “Ozempic Can’t Fix What Our Culture Has Broken”, in The New York Times, →ISSN:",
"text": "If GLP-1 drugs only treated diabetes and did not promote weight loss, they would still be medically groundbreaking.",
"type": "quotation"
},
{
"bold_text_offsets": [
[
202,
207
]
],
"ref": "2024 February 29, Edward Helmore, “Oprah Winfrey announces she is stepping down from WeightWatchers”, in The Guardian, →ISSN:",
"text": "An apparent conflict between WeightWatchers, which promotes a non-medical, points-based approach to food intake, and the talkshow host came in December when she told People magazine that she integrated GLP-1 drugs, brands that include Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, into her existing “holistic approach” of “regular exercise and other lifestyle tweaks”.",
"type": "quotation"
},
{
"bold_text_offsets": [
[
47,
53
]
],
"ref": "2025 April 29, Tammy LaGorce, “How Ozempic Is Shaping Weddings”, in The New York Times, →ISSN:",
"text": "Some brides say explicitly that they are using GLP-1s, while for others, Ms. Yang, who said she uses Mounjaro herself, has her suspicions.",
"type": "quotation"
},
{
"bold_text_offsets": [
[
134,
140
]
],
"ref": "2025 May 10, “WeightWatchers blames diet drugs and social media for Chapter 11 bankruptcy”, in FT Weekend, page 13:",
"text": "Its lawyers said it could no longer service a $1.6bn debt load because of an “evolution in consumer preferences and the rapid rise of GLP-1s”, and it was seeking an aggregate valuation of $700mn.",
"type": "quotation"
},
{
"bold_text_offsets": [
[
128,
134
]
],
"ref": "2025 May 15, Jennifer Weiner, “WeightWatchers Got One Thing Very Right”, in The New York Times, →ISSN:",
"text": "Those days are gone. WeightWatchers and its commercial diet program peers have struggled to maintain market share in the era of GLP-1s, the class of drugs that includes Ozempic, Wegovy and Mounjaro, which give users a much higher chance of success.",
"type": "quotation"
},
{
"bold_text_offsets": [
[
78,
84
]
],
"ref": "2025 August 25, Julie Creswell, “Krispy Kreme Bets on Big-Box Stores to Stay Fresh”, in The New York Times, New York, N.Y.: The New York Times Company, →ISSN, →OCLC:",
"text": "Consumers are also increasingly embracing wellness trends while others are on GLP-1s or medications that curb their desire to snack on sweet or salty foods.",
"type": "quotation"
}
],
"glosses": [
"Ellipsis of GLP-1 RA (“glucagon-like peptide-1 receptor agonist”), a class of drugs used for the medication of diabetes and weight loss."
],
"id": "en-GLP-1-en-noun-BXw-oJJL",
"links": [
[
"GLP-1 RA",
"GLP-1 RA#English"
],
[
"diabetes",
"diabetes"
],
[
"weight loss",
"weight loss"
]
],
"raw_glosses": [
"(informal, countable) Ellipsis of GLP-1 RA (“glucagon-like peptide-1 receptor agonist”), a class of drugs used for the medication of diabetes and weight loss."
],
"tags": [
"abbreviation",
"alt-of",
"countable",
"ellipsis",
"informal"
]
}
],
"word": "GLP-1"
}
{
"categories": [
"English countable nouns",
"English entries with incorrect language header",
"English lemmas",
"English multiword terms",
"English nouns",
"English terms spelled with numbers",
"English uncountable nouns",
"English words spelled without vowels",
"Pages with 1 entry",
"Pages with entries"
],
"forms": [
{
"form": "GLP-1s",
"tags": [
"plural"
]
}
],
"head_templates": [
{
"args": {
"1": "~",
"head": "GLP-1"
},
"expansion": "GLP-1 (countable and uncountable, plural GLP-1s)",
"name": "en-noun"
}
],
"lang": "English",
"lang_code": "en",
"pos": "noun",
"senses": [
{
"alt_of": [
{
"extra": "an incretin (gastrointestinal hormone)",
"word": "glucagon-like peptide-1"
}
],
"categories": [
"English initialisms",
"en:Hormones"
],
"glosses": [
"Initialism of glucagon-like peptide-1, an incretin (gastrointestinal hormone)."
],
"links": [
[
"biochemistry",
"biochemistry"
],
[
"glucagon-like peptide-1",
"w:glucagon-like peptide-1"
],
[
"incretin",
"incretin"
],
[
"gastrointestinal",
"gastrointestinal"
],
[
"hormone",
"hormone"
]
],
"raw_glosses": [
"(biochemistry) Initialism of glucagon-like peptide-1, an incretin (gastrointestinal hormone)."
],
"tags": [
"abbreviation",
"alt-of",
"countable",
"initialism",
"uncountable"
],
"topics": [
"biochemistry",
"biology",
"chemistry",
"microbiology",
"natural-sciences",
"physical-sciences"
]
},
{
"alt_of": [
{
"extra": "(“glucagon-like peptide-1 receptor agonist”), a class of drugs used for the medication of diabetes and weight loss",
"word": "GLP-1 RA"
}
],
"categories": [
"English countable nouns",
"English ellipses",
"English informal terms",
"English terms with quotations"
],
"examples": [
{
"bold_text_offsets": [
[
3,
8
]
],
"ref": "2023 October 9, Tressie McMillan Cottom, “Ozempic Can’t Fix What Our Culture Has Broken”, in The New York Times, →ISSN:",
"text": "If GLP-1 drugs only treated diabetes and did not promote weight loss, they would still be medically groundbreaking.",
"type": "quotation"
},
{
"bold_text_offsets": [
[
202,
207
]
],
"ref": "2024 February 29, Edward Helmore, “Oprah Winfrey announces she is stepping down from WeightWatchers”, in The Guardian, →ISSN:",
"text": "An apparent conflict between WeightWatchers, which promotes a non-medical, points-based approach to food intake, and the talkshow host came in December when she told People magazine that she integrated GLP-1 drugs, brands that include Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, into her existing “holistic approach” of “regular exercise and other lifestyle tweaks”.",
"type": "quotation"
},
{
"bold_text_offsets": [
[
47,
53
]
],
"ref": "2025 April 29, Tammy LaGorce, “How Ozempic Is Shaping Weddings”, in The New York Times, →ISSN:",
"text": "Some brides say explicitly that they are using GLP-1s, while for others, Ms. Yang, who said she uses Mounjaro herself, has her suspicions.",
"type": "quotation"
},
{
"bold_text_offsets": [
[
134,
140
]
],
"ref": "2025 May 10, “WeightWatchers blames diet drugs and social media for Chapter 11 bankruptcy”, in FT Weekend, page 13:",
"text": "Its lawyers said it could no longer service a $1.6bn debt load because of an “evolution in consumer preferences and the rapid rise of GLP-1s”, and it was seeking an aggregate valuation of $700mn.",
"type": "quotation"
},
{
"bold_text_offsets": [
[
128,
134
]
],
"ref": "2025 May 15, Jennifer Weiner, “WeightWatchers Got One Thing Very Right”, in The New York Times, →ISSN:",
"text": "Those days are gone. WeightWatchers and its commercial diet program peers have struggled to maintain market share in the era of GLP-1s, the class of drugs that includes Ozempic, Wegovy and Mounjaro, which give users a much higher chance of success.",
"type": "quotation"
},
{
"bold_text_offsets": [
[
78,
84
]
],
"ref": "2025 August 25, Julie Creswell, “Krispy Kreme Bets on Big-Box Stores to Stay Fresh”, in The New York Times, New York, N.Y.: The New York Times Company, →ISSN, →OCLC:",
"text": "Consumers are also increasingly embracing wellness trends while others are on GLP-1s or medications that curb their desire to snack on sweet or salty foods.",
"type": "quotation"
}
],
"glosses": [
"Ellipsis of GLP-1 RA (“glucagon-like peptide-1 receptor agonist”), a class of drugs used for the medication of diabetes and weight loss."
],
"links": [
[
"GLP-1 RA",
"GLP-1 RA#English"
],
[
"diabetes",
"diabetes"
],
[
"weight loss",
"weight loss"
]
],
"raw_glosses": [
"(informal, countable) Ellipsis of GLP-1 RA (“glucagon-like peptide-1 receptor agonist”), a class of drugs used for the medication of diabetes and weight loss."
],
"tags": [
"abbreviation",
"alt-of",
"countable",
"ellipsis",
"informal"
]
}
],
"word": "GLP-1"
}
Download raw JSONL data for GLP-1 meaning in English (4.5kB)
This page is a part of the kaikki.org machine-readable English dictionary. This dictionary is based on structured data extracted on 2026-03-25 from the enwiktionary dump dated 2026-03-03 using wiktextract (05c257f and 9d9a410). The data shown on this site has been post-processed and various details (e.g., extra categories) removed, some information disambiguated, and additional data merged from other sources. See the raw data download page for the unprocessed wiktextract data.
If you use this data in academic research, please cite Tatu Ylonen: Wiktextract: Wiktionary as Machine-Readable Structured Data, Proceedings of the 13th Conference on Language Resources and Evaluation (LREC), pp. 1317-1325, Marseille, 20-25 June 2022. Linking to the relevant page(s) under https://kaikki.org would also be greatly appreciated.